Cargando…

Metabolomics to Predict Antiviral Drug Efficacy in COVID-19

Detalles Bibliográficos
Autores principales:	Migaud, Marie, Gandotra, Sheetal, Chand, Hitendra S., Gillespie, Mark N., Thannickal, Victor J., Langley, Raymond J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462337/ https://www.ncbi.nlm.nih.gov/pubmed/32574504 http://dx.doi.org/10.1165/rcmb.2020-0206LE

Ejemplares similares

A metabolomic endotype of bioenergetic dysfunction predicts mortality in critically ill patients with acute respiratory failure
por: Langley, Raymond J., et al.
Publicado: (2021)

66942 Metabolomic endotype of bioenergetic dysfunction predicts mortality in critically ill patients with acute respiratory failure
por: Langley, Raymond J., et al.
Publicado: (2021)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

Host-targeting oral antiviral drugs to prevent pandemics
por: Dwek, Raymond A, et al.
Publicado: (2022)

Modelling the evolution of drug resistance in the presence of antiviral drugs
por: Wu, Jianhong, et al.
Publicado: (2007)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Monkeypox treatment options: current status of antiviral drugs – a correspondence
por: Ganapthy, Dhanraj, et al.
Publicado: (2023)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Combining immunomodulators and antivirals for COVID-19
por: Chen, Luke Y C, et al.
Publicado: (2021)

Combining immunomodulators and antivirals for COVID-19 – Authors' reply
por: Almansa, Raquel, et al.
Publicado: (2021)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Early triple antiviral therapy for COVID-19
por: Lee, Nelson, et al.
Publicado: (2020)

Putative antiviral effects of propofol in COVID-19
por: Wei, Penghui, et al.
Publicado: (2021)

Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects
por: Chakraborty, Sandip, et al.
Publicado: (2022)

Antiviral effects of oleandrin
por: Newman, R., et al.
Publicado: (2021)

The Long and the Short of It: Is “Long COVID” More Than Slow Resolution of the Acute Disease?
por: Gandotra, Sheetal, et al.
Publicado: (2021)

Functional exhaustion of antiviral lymphocytes in COVID-19 patients
por: Zheng, Meijuan, et al.
Publicado: (2020)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Early triple antiviral therapy for COVID-19 – Authors' reply
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland
por: Tibble, Holly, et al.
Publicado: (2023)

WHO Living Guidelines on antivirals for COVID-19 are evidence-based
por: Owen, Andrew, et al.
Publicado: (2023)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

The use of careFiji app for contact tracing during the COVID-19 pandemic: Digital gap and challenges faced in Fiji
por: Chand, Shivnay S., et al.
Publicado: (2021)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis
por: Saito, Shigeki, et al.
Publicado: (2022)

Rationale of receptor-based antivirals against SARS
Publicado: (2013)

Antiviral pills: A potential game-changing therapy against COVID-19
por: Dhawan, Manish, et al.
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation?
por: Hübner, Yannis R., et al.
Publicado: (2023)

COVID-19 and vaccination rollout in Fiji: Challenges caused by digital platform
por: Chand, Aneesh A.
Publicado: (2021)

Response to “Comment on ‘Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research’”
por: Langley, Gill
Publicado: (2016)

Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19
por: Nainu, Firzan, et al.
Publicado: (2023)

Mpox virus infects and injures human kidney organoids, but responding to antiviral treatment
por: Li, Pengfei, et al.
Publicado: (2023)

Weight of Vesical Stones
por: Swan, J. E., et al.
Publicado: (1914)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Author's overview: identifying SARS-CoV-2 antiviral compounds
por: Diffley, John F.X.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d6fkb4chhoqk5ahum08tssin86